WASHINGTON — Moderna said its mRNA COVID-19 vaccine, which is already approved for adults in the EU, is highly effective in children over 12 years old.

The results of a trial of 3,700 12- to 17-year-olds in the US could pave the way towards the vaccine being made available to younger age groups.

After two doses of the COVID-19 vaccine, there were no cases of the virus in study participants, Moderna said in a press release on Tuesday, meaning it was 100% effective at preventing COVID-19.

The vaccine was 93 percent effective in children ages 12-17 two weeks after a single dose, the company added.

“We are encouraged that mRNA-1273 was highly effective at preventing COVID-19 in adolescents,” said Stéphane Bancel, Chief Executive Officer of Moderna, in a statement.

“We will submit these results to the US FDA and regulators globally in early June and request authorization. We remain committed to doing our part to help end the COVID-19 pandemic.” — Euronews